MaxCyte stock has November 10, 2026 earnings date
Published on 10/17/2026 at 21:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming date and valuation
- MaxCyte will host its next earnings call on November 10, 2026.
- The trailing P/E was minus 3.89 at a USD 134.2 million market value on October 16, 2026.
- MaxCyte stock closed at USD 1.30 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, unchanged from the prior close.
- Volume reached 1,006,501 shares versus an average of 827,795 on October 16, 2026.
MaxCyte's next earnings call is scheduled for November 10, 2026, at 4:30 p.m. ET, according to MaxCyte. The stock closed at USD 1.30 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, unchanged from the prior close.
Valuation metrics stay negative
MaxCyte had a trailing P/E of minus 3.89 on October 16, 2026, alongside a market capitalization of USD 134.2 million. The negative ratio reflects the company's loss-making earnings base, while the market value provides a clear scale marker for the listed cell-engineering specialist.
Trading volume exceeds its average
Trading volume reached 1,006,501 shares on October 16, 2026, compared with an average volume of 827,795 shares. That puts the session volume 21.62 percent above the average. The 52-week range was USD 0.64 to USD 1.81, leaving the closing price 28.18 percent below the high and 103.13 percent above the low.
On October 14, 2026, MaxCyte had published preliminary third-quarter figures and updated its full-year outlook, according to MaxCyte. The dated release remains background for this market report rather than a fresh trading explanation.
November 10 sets the next checkpoint
The company has put November 10, 2026 on its calendar for third-quarter results and a 4:30 p.m. ET conference call. MarketBeat lists consensus expectations of a loss of USD 0.08 per share and revenue of USD 7.39 million for the quarter.
Comparison with peers
MaxCyte (Nasdaq, USD): unchanged, P/E minus 3.89, market capitalization USD 134.2 million
Beam Therapeutics (Nasdaq, USD): minus 5.10 percent, P/E minus 27.29, market capitalization USD 2.4 billion
Intellia Therapeutics (Nasdaq, USD): plus 0.71 percent, P/E minus 3.40, market capitalization USD 1.6 billion
Market position before the next report
MaxCyte's closing level sits well below its 52-week high, while volume was higher than its recent average. The November reporting date is the next clearly scheduled company event for the stock.
The last Nasdaq closing price was USD 1.30 on October 16, 2026 at 4:00 p.m. ET.
Market context: Market report S&P 500.
